Could a common diabetes drug help heal scarred hearts?
NCT ID NCT07294495
First seen Jan 05, 2026 · Last updated May 25, 2026 · Updated 20 times
Summary
This study tests whether henagliflozin, a drug used for diabetes, can reduce scarring in the heart muscle of people with a condition called non-obstructive hypertrophic cardiomyopathy (HCM). The heart muscle is thickened and scarred, which can lead to problems like heart failure. 150 adults will receive either the drug or a placebo for 6 months, and special scans will measure changes in scarring. The goal is to see if the drug can control the disease and improve heart health.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HCM - HYPERTROPHIC CARDIOMYOPATHY are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Shanghai East Hospital
Shanghai, Shanghai Municipality, 200120, China
Conditions
Explore the condition pages connected to this study.